Table 4.

Trials for Prevention of VTE in Total Hip and Knee Replacement

TSOA and Randomized Clinical Trial	Enoxaparin Treatment Dose	Days of TSOA Treatment	VTE Risk Difference, %	Bleeding Risk Difference, %
Dabigatran
RE‐MOBILIZE51	30 mg twice daily	12 to 15	5.8*	0.8*
RE‐MODEL52	40 mg once daily	6 to 10	1.3	0.2
RE‐NOVATE53	40 mg once daily	28 to 35	0.7	0.4
RE‐NOVATE II54	40 mg once daily	28 to 35	1.1	0.5
Rivaroxaban
RECORD 144	40 mg once daily	31 to 39	2.6	0.7
RECORD 245	40 mg once daily	31 to 39	7.3	0.6
RECORD 348	40 mg once daily	10 to 14	9.1	0.6
RECORD 449	30 mg twice daily	10 to 14	3.2	0.7
Apixaban
ADVANCE‐155	30 mg twice daily	10 to 14	0.2	1.5*
ADVANCE‐256	40 mg once daily	10 to 14	9.3	1.2*
ADVANCE‐357	40 mg once daily	35	2.5	0.2*

TSOA indicates target‐specific oral anticoagulant; VTE, venous thromboembolism.

^*Significant risk reduction in favor of enoxaparin in prevention of VTE or death.

^*Reduction in major and clinically relevant nonmajor bleeding rates in favor of TSOA.